EP395

DRUG4 trials

Sponsors

EpiEndo Pharmaceuticals

Conditions

Adult ALLCOPDChronic Obstructive Pulmonary DiseaseHealthy Volunteer

Phase 1

Single and Multiple Ascending Dose Study With EP395

CompletedNCT04819854

EpiEndo PharmaceuticalsAdult ALL

Start: 2021-04-05End: 2022-03-22Updated: 2026-04-29

Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults

CompletedNCT05516316

EpiEndo PharmaceuticalsChronic Obstructive Pulmonary Disease, COPD

Start: 2022-10-11End: 2023-06-21Updated: 2026-04-29

Clinical Trial Investigating the Effects of EP395 Following an Inhaled Endotoxin Challenge in Healthy Adults

CompletedNCT06677918

EpiEndo PharmaceuticalsHealthy Volunteer

Start: 2025-02-20End: 2025-08-25Updated: 2025-11-20

Phase 2

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

CompletedNCT05572333

EpiEndo PharmaceuticalsChronic Obstructive Pulmonary Disease, COPD

Start: 2022-11-22End: 2023-11-24Updated: 2026-07-01

Related Papers

A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients

ERJ Open Research2025-12-04